BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) announced that Thalidomide Pharmion has been granted full marketing authorization by the European Commission for use in combination with melphalan and prednisone as a treatment for patients with newly diagnosed multiple myeloma. In June 2007, the European Commission granted the Company’s REVLIMID® full marketing authorization as the first oral treatment in more than 40 years for patients with multiple myeloma who have received at least one prior therapy. These approvals confirm the leading role of Celgene in blood cancer research and innovative oral therapies.
